Journal Mobile Options
Table of Contents
Vol. 72, No. 4, 2011
Issue release date: December 2011
Gynecol Obstet Invest 2011;72:269–273
(DOI:10.1159/000328719)

Effect of Progesterone as a Tocolytic and in Maintenance Therapy during Preterm Labor

Arikan I. · Barut A. · Harma M. · Harma I.M.
Department of Gynecology and Obstetrics, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Aims: To assess the efficacy of vaginal micronized natural progesterone as a tocolytic and in maintenance therapy during threatened preterm birth. Methods: Eighty-three women with symptoms of threatened preterm birth were either randomized to study groups receiving tocolytic treatment combined with intravaginal micronized natural progesterone (200 mg daily) or to a control group receiving only tocolysis. Results: Micronized natural progesterone treatment resulted in a prolonged latency period of 32.1 ± 17.8 versus 21.2 ± 16.3 days in the control group and heavier birth weights of 2,982.8 ± 697.8 g versus 2,585.3 ± 746.6 g. No significant differences were found between the groups in admission to the neonatal intensive care unit, stay at the neonatal intensive care unit, need for a mechanical ventilator, respiratory distress syndrome or neonatal sepsis. Conclusion: The treatment of threatened preterm birth with tocolytics combined with intravaginal micronized natural progesterone significantly prolonged pregnancy and increased birth weight. However, an improvement in adverse perinatal outcomes was not observed.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kauppila A, Hartikainen-Sorri AL, Jänne O, Tuimala R, Järvinen PA: Suppression of threatened premature labor by administration of cortisol and 17α-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol 1980;138:404–408.
  2. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, Barrat J: The potential tocolytic effect of natural progesterone administration on premature. Am J Obstet Gynecol 1986;154:525–529.
  3. Noblot G, Audra P, Dargent D, Faguer B, Mellier G: The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203–209.
  4. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH: Progesterone and the risk of preterm birth among women with a short cervix. Fetal Medicine Foundation Second Trimester Screening Group. N Engl J Med 2007;357:462–469.
  5. DeFranco EA, O’Brien JM, Adair CD, et al: Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697–705.
  6. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M: Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–424.
  7. Meis PJ, Klebanoff M, Thom E, et al: Prevention of recurrent preterm delivery by 17α-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–2385.
  8. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al: The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996;334:567–572.
  9. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH, et al: Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 2006;27:362–367.
  10. Grimes-Dennis J, Berghella V: Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol 2007;19:191–195.
  11. Berghella V, Owen J, MacPherson C, Yost N, Swain M, Dildy GA 3rd, et al: Natural history of cervical funneling in women at high risk for spontaneous preterm birth. Obstet Gynecol 2007;109:863–869.
  12. Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, et al: Increased recurrence of preterm delivery with early cessation of 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:224: e1–4.
  13. Lang CT, Iams JD: Goals and strategies for prevention of preterm birth: an obstetric perspective. Pediatr Clin North Am 2009;56:537–563.
  14. World Health Organization: Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO October 14, 1976. Acta Obstet Gynecol Scand 1977;56:247–253.
  15. Tita AT, Rouse DJ: Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009;200:219–224.
  16. Borna S, Sahabi N: Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58–63.
  17. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A: Cervical length changes during preterm cervical ripening: effects of 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453–454.
  18. Thornton JG: Maintenance tocolysis. BJOG 2005;112(suppl 1):118–121.
  19. Dodd JM, Crowther CA, Dare MR, Middleton P: Oral β-mimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2006;CD003927.
  20. Papatsonis D, Flenady V, Liley H: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2009;CD005938.
  21. Papiernik-Berkhauer E: Double-blind study of an agent to prevent preterm delivery among women at increased risk. Edition Schering, series IV, 1970, pp 65–68.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50